Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)Shu-Peng Zou, Minghui Sun, Mengling Ouyang et al.|Expert Opinion on Drug Safety|2023Cited by 16